Embodiments disclosed herein relates to ganglioside GM3-containing mixed lipids nanoparticles having an overall size between 60-100 nm, the making thereof and the uses. The nanoparticles selectively targeted to CD169+ expressing cells such as dendritic cells and macrophage. The nanoparticles are endocytosed by the CD169+ expressing cells.

Compositions are provided according to aspects of the present invention that include a hydrogel and a liner, wherein a surface of the hydrogel dissociably-engages a surface of the liner. Compositions are provided according to aspects of the present invention that include a hydrogel and a hydrophobic glue, wherein at least a portion of the gel network of the hydrogel is occupied by the hydrophobic glue. Reverse coaling processes and articles of manufacture made by reverse coating processes are provided according to aspects of the present invention. Compositions are provided according to aspects of the present invention that include a hydrogel and a substrate, wherein: the hydrogel comprises a polymer network; the substrate comprises a surface comprising a polymer network; and the polymer network of the hydrogel and the polymer network of the surface are entangled.

Amphiphilic oligonucleotide conjugates that enhance adjuvant function are disclosed. The conjugates typically include: a lipophilic component, and conjugated thereto (directly or indirectly) an immunomodulating oligonucleotide that, if it were not conjugated to the lipophilic component, would suppress TLR7 and/or TLR8 stimulation. In the presence of albumin, these conjugates significantly enhance adjuvant function, in particular the function of TLR7/8-mediated adjuvants such as an imidazoquinolinamine. The conjugates can be administered, along with an adjuvant compound, to a subject in order to cause and/or enhance an immune response (for instance, to an infectious agent or a cancer antigen) in the subject.

Disclosed herein are nanoparticle compositions containing that may be created by functionalizing polyethylenimine (PEI) with fatty acids and carboxylate terminated poly(ethylene glycol) (PEG). The disclosed compositions may be delivered to an individual in need thereof via delivery into blood circulation, where the nanoparticle compositions show an exceptionally high specificity to the pulmonary microvascular endothelium with minimal targeting of other cell types in the lung, to provide delivery of therapeutic agents such as stabilized nucleic acids. Methods of using the compositions are also disclosed.

The present disclosure relates to extracellular vesicles (e.g., exosomes) comprising a biologically active molecule covalently linked to the extracellular vesicle via an anchoring moiety, which may be useful as an agent for the prophylaxis or treatment of cancer or other diseases. Also provided herein are methods for producing the extracellular vesicles and methods for using the extracellular vesicles to treat diseases or disorders.

New aminooxylipids of general formula I, wherein n.sub.1=5-30 and X is polymethylene linker of the general formula II where n.sub.2=2-10, or X is polyethylene glycol linker of the general formula III, wherein n.sub.3=1-14 are provided. A method of preparation of the aminooxylipids of general formula I characterized in that the acylation of N-tert-butoxycarbonyl-polymethylenediamine {(CH.sub.3).sub.3C—O—(C═O)—HN—(CH.sub.2).sub.n—NH.sub.2, n=2-13}, or N-tert-butoxycarbonyl-polyethyleglycoldiamine {(CH.sub.3).sub.3C—O—(C═O)—HN—(CH.sub.2).sub.2—[O—(CH.sub.2)].sub.n—O—(CH.sub.2).sub.2NH.sub.2, n=1-14} with in position C(2) symmetrically branched fatty acids of general formula IV, wherein n.sub.1=5-30, in the presence of condensation reagent, or from acid of general formula IV derived acylchloride of general formula V wherein n.sub.1=5-30, produces N-Boc-aminolipids of general formula VI, wherein n.sub.1=5-30 a X is polymethylene linker of the general formula II or X is polyethylene glycol linker of the general formula III.

Amphiphilic oligonucleotide conjugates that enhance adjuvant function are disclosed. The conjugates typically include: a lipophilic component, and conjugated thereto (directly or indirectly) an immunomodulating oligonucleotide that, if it were not conjugated to the lipophilic component, would suppress TLR7 and/or TLR8 stimulation. In the presence of albumin, these conjugates significantly enhance adjuvant function, in particular the function of TLR7/8-mediated adjuvants such as an imidazoquinolinamine. The conjugates can be administered, along with an adjuvant compound, to a subject in order to cause and/or enhance an immune response (for instance, to an infectious agent or a cancer antigen) in the subject.

Disclosed are lipid compounds comprising imidazole heads and lipidoid nanoparticles (LNPs) comprising the lipidoid compounds disclosed herein for efficient nucleic acid delivery to T cells.

The present invention relates, in general terms, to methods of reducing the formation of post-surgery tissue adhesion in a subject in need thereof by administering an adhesion barrier composition. The present invention also relates to methods of preventing the formation of tissue adhesion during or post-surgery in a subject in need thereof. The adhesion barrier composition comprises sporopollenin and a biodegradable polymer. The present invention also relates to methods of fabricating the adhesion barrier composition.

A nano small peptide FG and its use in preparation of drugs for treating and preventing fundus vascular diseases are provided. The artificially synthesized nano small peptide has a molecular formula of X-FFVLK-KNKAAKG (SEQ ID NO:1), wherein the X is C.sub.12, C.sub.14, C.sub.16, or C.sub.18. The nano small peptide of the present invention can specifically select receptors to encapsulate sSema4D protein, and the concentration of sSema4D is effectively reduced, so that the sSema4D is unable to bind to any receptors, thus changing the shortcoming of few inhibitory targets of antibody drugs. The nano small peptide molecule with a simple structure can be mixed with antibody drugs without causing mutual immune reactions, so as to achieve the effect of reducing multiple pro-angiogenesis molecules.